Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement.
Maturitas
; 131: 91-101, 2020 Jan.
Article
em En
| MEDLINE
| ID: mdl-31740049
ABSTRACT
INTRODUCTION:
Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes.AIM:
The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women. MATERIALS ANDMETHODS:
Literature review and consensus of expert opinion. SUMMARYRECOMMENDATIONS:
Awareness of depressive symptoms, early detection, standardized diagnostic procedures, personalized treatment and a suitable follow-up schedule need to be integrated into healthcare systems worldwide. Recommended treatment comprises antidepressants, psychosocial therapies and lifestyle changes. Alternative and complementary therapies, although widely used, may help with depression, but a stronger evidence base is needed. Although not approved for this indication, menopausal hormone therapy may improve depressive symptoms in peri- but not in postmenopausal women, especially in those with vasomotor symptoms.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pós-Menopausa
/
Depressão
/
Transtorno Depressivo Maior
/
Perimenopausa
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article